(Q37027137)

17 August 2017

1 reference

title

Bridging the knowledge gaps in vaccine design (English)

1 reference

17 August 2017

1 reference

1 reference

knowledge gap hypothesis

1 reference

1 reference

1

Rino Rappuoli

1 reference

17 August 2017

language of work or name

1 reference

1 December 2007

1 reference

17 August 2017

1 reference

17 August 2017

volume

25

1 reference

17 August 2017

issue

12

1 reference

17 August 2017

page(s)

1361-1366

1 reference

https://scigraph.springernature.com/pub.10.1038/nbt1207-1361

17 August 2017

exact match

0 references

cites work

The diphtheria and pertussis components of diphtheria-tetanus toxoids-pertussis vaccine should be genetically inactivated mutant toxins

1 reference

https://api.crossref.org/works/10.1038%2FNBT1207-1361

7 January 2021

Medicine. The intangible value of vaccination

1 reference

https://api.crossref.org/works/10.1038%2FNBT1207-1361

7 January 2021

Mutants of pertussis toxin suitable for vaccine development

1 reference

https://api.crossref.org/works/10.1038%2FNBT1207-1361

7 January 2021

A Controlled Trial of Two Acellular Vaccines and One Whole-Cell Vaccine against Pertussis

1 reference

https://api.crossref.org/works/10.1038%2FNBT1207-1361

7 January 2021

Virus-like particles as immunogens

1 reference

https://api.crossref.org/works/10.1038%2FNBT1207-1361

7 January 2021

Use of viral vectors for the development of vaccines

1 reference

https://api.crossref.org/works/10.1038%2FNBT1207-1361

7 January 2021

Pneumococcal vaccine development

1 reference

https://api.crossref.org/works/10.1038%2FNBT1207-1361

7 January 2021

Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine

1 reference

https://api.crossref.org/works/10.1038%2FNBT1207-1361

7 January 2021

Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage

1 reference

https://api.crossref.org/works/10.1038%2FNBT1207-1361

7 January 2021

Population-based analysis of meningococcal disease mortality in the United States: 1990-2002.

1 reference

https://api.crossref.org/works/10.1038%2FNBT1207-1361

7 January 2021

Recent trends in meningococcal epidemiology and current vaccine recommendations

1 reference

https://api.crossref.org/works/10.1038%2FNBT1207-1361

7 January 2021

Realities and enigmas of human viral influenza: pathogenesis, epidemiology and control

1 reference

https://api.crossref.org/works/10.1038%2FNBT1207-1361

7 January 2021

https://api.crossref.org/works/10.1038%2FNBT1207-1361

1 reference

7 January 2021

Current progress in the development of HIV vaccines

1 reference

https://api.crossref.org/works/10.1038%2FNBT1207-1361

7 January 2021

Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum

1 reference

https://api.crossref.org/works/10.1038%2FNBT1207-1361

7 January 2021

Hypothesis: how licensed vaccines confer protective immunity.

1 reference

https://api.crossref.org/works/10.1038%2FNBT1207-1361

7 January 2021

Experience with registered mucosal vaccines

1 reference

https://api.crossref.org/works/10.1038%2FNBT1207-1361

7 January 2021

Mucosal immunity and viral infections

1 reference

https://api.crossref.org/works/10.1038%2FNBT1207-1361

7 January 2021

Comparative evaluation of immunization with live attenuated and inactivated poliovirus vaccines.

1 reference

https://api.crossref.org/works/10.1038%2FNBT1207-1361

7 January 2021

Varicella-zoster vaccine for the prevention of herpes zoster

1 reference

https://api.crossref.org/works/10.1038%2FNBT1207-1361

7 January 2021

Live attenuated versus inactivated influenza vaccine in infants and young children.

1 reference

https://api.crossref.org/works/10.1038%2FNBT1207-1361

7 January 2021

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

1 reference

https://api.crossref.org/works/10.1038%2FNBT1207-1361

7 January 2021

Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand

1 reference

https://api.crossref.org/works/10.1038%2FNBT1207-1361

7 January 2021

An HIV vaccine--evolving concepts

1 reference

https://api.crossref.org/works/10.1038%2FNBT1207-1361

7 January 2021

Prospects for a vaccine against the hepatitis C virus

1 reference

https://api.crossref.org/works/10.1038%2FNBT1207-1361

7 January 2021

AIDS research. Promising AIDS vaccine's failure leaves field reeling

1 reference

https://api.crossref.org/works/10.1038%2FNBT1207-1361

7 January 2021

https://api.crossref.org/works/10.1038%2FNBT1207-1361

1 reference

7 January 2021

Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing.

1 reference

https://api.crossref.org/works/10.1038%2FNBT1207-1361

7 January 2021

A universal vaccine for serogroup B meningococcus

1 reference

https://api.crossref.org/works/10.1038%2FNBT1207-1361

7 January 2021

Genome analysis of multiple pathogenic isolates of Streptococcus agalactiae: implications for the microbial "pan-genome"

1 reference

https://api.crossref.org/works/10.1038%2FNBT1207-1361

7 January 2021

The microbial pan-genome

1 reference

https://api.crossref.org/works/10.1038%2FNBT1207-1361

7 January 2021

Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1038%2FNBT1207-1361

7 January 2021

Characterization and identification of vaccine candidate proteins through analysis of the group A Streptococcus surface proteome.

1 reference

https://api.crossref.org/works/10.1038%2FNBT1207-1361

7 January 2021

The pan-genome: towards a knowledge-based discovery of novel targets for vaccines and antibacterials

1 reference

https://api.crossref.org/works/10.1038%2FNBT1207-1361

7 January 2021

Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro

1 reference

https://api.crossref.org/works/10.1038%2FNBT1207-1361

7 January 2021

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1038%2FNBT1207-1361

7 January 2021

Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1.

1 reference

https://api.crossref.org/works/10.1038%2FNBT1207-1361

7 January 2021

Structural definition of a conserved neutralization epitope on HIV-1 gp120

1 reference

https://api.crossref.org/works/10.1038%2FNBT1207-1361

7 January 2021

Post-genomic vaccine development

1 reference

https://api.crossref.org/works/10.1038%2FNBT1207-1361

7 January 2021

Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II-restricted responses

1 reference

https://api.crossref.org/works/10.1038%2FNBT1207-1361

7 January 2021

Expanding the effector CD4 T-cell repertoire: the Th17 lineage.

1 reference

https://api.crossref.org/works/10.1038%2FNBT1207-1361

7 January 2021

Th17 cell induction and immune regulatory effects.

1 reference

https://api.crossref.org/works/10.1038%2FNBT1207-1361

7 January 2021

Interleukin-10 determines viral clearance or persistence in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNBT1207-1361

7 January 2021

Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation

1 reference

https://api.crossref.org/works/10.1038%2FNBT1207-1361

7 January 2021

Long-term in vivo provision of antigen-specific T cell immunity by programming hematopoietic stem cells

1 reference

https://api.crossref.org/works/10.1038%2FNBT1207-1361

7 January 2021

Targeting lentiviral vectors to specific cell types in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNBT1207-1361

7 January 2021

T cell memory and protective immunity by vaccination: is more better?

1 reference

https://api.crossref.org/works/10.1038%2FNBT1207-1361

7 January 2021

The contribution of immunology to the rational design of novel antibacterial vaccines

1 reference

https://api.crossref.org/works/10.1038%2FNBT1207-1361

7 January 2021

Identifiers

DOI

10.1038/NBT1207-1361

1 reference

17 August 2017

1 reference